...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Platelets >ThromboFixtrade mark Platelet Stabilizer: Advances in clinical platelet analyses by flow cytometry?
【24h】

ThromboFixtrade mark Platelet Stabilizer: Advances in clinical platelet analyses by flow cytometry?

机译：ThromboFixtrade mark血小板稳定剂：通过流式细胞仪进行临床血小板分析的进展？

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Platelet flow cytometry is restricted by spontaneous platelet activation in unfixed samples or by significant alterations of platelet performance caused by the use of fixatives. Aim of this study was to evaluate the new platelet stabilizer ThromboFixtrade mark for clinical diagnostics.Methods: Whole blood samples with or without addition of a weak (ADP) or strong (TRAP-6) agonist were fixed with either ThromboFix or paraformaldehyde (PFA) and stored for different periods of time for up to 7 days. Samples were then incubated with either CD41 and CD62P or CD42b and CD45 monoclonal antibodies and analyzed by flow cytometry.Results: The numbers of platelets, microparticles and aggregates remained stable for 7 days after treatment with ThromboFix but not with PFA due to an increasing aggregate formation after 3 days. Platelet activation was restricted to less than 1% of CD62P positive events in resting samples without a significant difference compared to an unfixed reference sample. Fixation, however, significantly reduced CD62P expression after stimulation (P < 0.05). Stabilized by ThromboFix, the level of platelet activation remained unchanged in resting and ADP stimulated samples for 7 days but decreased moderately with time after a strong stimulation with TRAP-6 (P < 0.01). After PFA fixation, intact CD62P antigen disappeared from the platelet surface within hours (P < 0.01). ThromboFix reduced the formation of platelet-leukocyte conjugates significantly (P < 0.05) and, in contrast to PFA, failed to stabilize the already formed conjugates.Conclusion: In clinical situations without immediate access to a flow cytometer, ThromboFix is helpful in the flow cytometric analysis of the platelet activation marker CD62P. It should not be used for the investigation of platelet-leukocyte conjugate formation.
机译：血小板流式细胞术受到未固定样品中血小板的自发激活或由于使用固定剂引起的血小板性能的显着改变的限制。这项研究的目的是评估用于临床诊断的新型血小板稳定剂ThromboFixtrademarks.Methods：用或不使用ThromboFix或多聚甲醛（PFA）固定添加或不添加弱（ADP）或强（TRAP-6）激动剂的全血样品。并在不同的时间段最多存储7天。然后将样品与CD41和CD62P或CD42b和C​​D45单克隆抗体一起孵育，并通过流式细胞仪进行分析。结果：血小板，微粒和聚集体的数量在用ThromboFix处理后7天保持稳定，但由于聚集体形成增加，因此不稳定3天后。与未固定的参考样品相比，静息样品中的血小板活化仅限于CD62P阳性事件的1％以下，而无显着差异。然而，固定后，刺激后CD62P表达显着降低（P <0.05）。通过ThromboFix稳定，在静止和ADP刺激的样本中血小板活化水平保持7天不变，但在用TRAP-6强烈刺激后随时间逐渐降低（P <0.01）。 PFA固定后，完整的CD62P抗原在数小时内从血小板表面消失（P <0.01）。 ThromboFix显着减少了血小板-白细胞结合物的形成（P <0.05），并且与PFA相比，未能稳定已经形成的结合物。血小板活化标记CD62P的分析。它不应用于研究血小板-白细胞结合物的形成。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号